Skip to main content
Mary Cushman on Muck Rack

Mary Cushman

Burlington
As seen in: National Institutes of Health, Color Research & Application, Nature, Wiley, Occupational and Environmental Medicine (OEM), U.S. News and World Report, JAMA (The Journal of the American Medical Association), JAMA: Journal of the American Medical Association, Everyday Health, The Lancet and
Hematologist, University Distinguished Professor & Vice Chair for Emerging Researchers, @UVMDeptMed. Co-Director @UVMHeartBrain. Views mine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mary

Contact Mary, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals

|
By Brendon L Neuen, Rupert W. Major, Morgan E. Grams, Yingying Sang, Josef Coresh, Shoshana H. Ballew, Aditya Surapaneni, Natalia Alencar de Pinho, Johan Ärnlöv, Clare Arnott, Samira Bell, Jarett Berry, Hermann Brenner, Elizabeth L Ciemins, Alexander Chang, Mary Cushman, James de Lemos, Juan Miguel Diaz-Tocados, Alfredo E. Farjat, Robert Fletcher, Ron T Gansevoort, Hiddo J. L. Heerspink, William G Herrington, Chuan Hong, Shih-Jen Hwang, Simerjot K Jassal, Philip A. Kalra, Ronit Katz, Sadiya Khan, Csaba P. Kovesdy, Florian Kronenberg, Jennifer Lees, Donald M. Lloyd-Jones, José Geraldo Mill, David Naimark, Chiadi E. Ndumele, Kevan R. Polkinghorne, Bruce M. Psaty, Patrick Schloemer, Michael G. Shlipak, Prabin Shrestha, Zean Song, Natalie Staplin, Dominik Steubl, Priya Vart, Frank L. J. Visseren, Mark Woodward, Kazumasa Yamagishi, Bessie A. Young, Charumathi Sabanayagam, José M. Valdivielso
| Nature Verified
Abstract The American Heart Association’s PREVENT equations estimate risk of total cardiovascular disease (CVD), atherosclerotic CVD (ASCVD), and heart failure (HF) to guide lipid and blood pressure-lowering therapy in people ages 30 to 79 years in the United States. The SCORE2 risk algorithm is used to estimate CVD risk for similar purposes in people ages 40 and older in Europe. Neither set of equations has been comprehensively validated in global observational cohorts and randomized trials.
Open in Who Shared Issue with article?

AHA/ACC Acute Pulmonary Embolism Clinical Categories: Perspectives on Development and Application

|
By Gregory Piazza, Mary Cushman
| JACC (Journal of the American College of Cardiology)
JACC Journals › JACC › Archives › Vol. 87 No. 13 : JACC Volume 87, Number 13 Get full access to this article View all available purchase options and get full access to this article. References 1. Zuin M., Bikdeli B., Ballard-Hernandez J., et al. International clinical practice guideline recommendations for acute pulmonary embolism: harmony, dissonance, and silence. J Am Coll Cardiol. 2024;84:16: 1561-1577. https://doi.org/10.1016/j.jacc.2024.07.044. 2. Creager M.A., Barnes G.D., Giri J., et al.
Open in Who Shared Issue with article?

Antiphospholipid antibodies and cardiovascular thrombosis

|
By Sina Rashedi, Hannah Leyva Verified, Saman Siddiqui, Syed Abbas Bukhari, Mariana B. Pfeferman, Nathan Watson, Francisco Ujueta, Mehrdad Zarghami, Yogendra Kanthi, David Jimenez, Manuel Monreal, Deborah M. Siegal, Geoffrey D. Barnes, John Eikelboom, Michelle L. O’Donoghue, Christian T. Ruff, Mattia Galli, Brittany Weber, Samuel Z. Goldhaber, Sacha Uljon, Saskia Middeldorp, Renato D. Lopes, David Garcia, David García, Gregory Y. H. Lip, Jean M. Connors, Harlan M. Krumholz, Jason Knight, Giuseppe Lippi, Mitchell S. V. Elkind, Mary Cushman, Karen H Costenbader, Gregory Piazza, Behnood Bikdeli, Bassil Bacare, Jeffery I. Weitz
| Nature Verified
Abstract Antiphospholipid antibodies (aPL) are directed against phospholipids and phospholipid-binding proteins. Laboratory assays used to detect aPL include serological tests for aPL against β2-glycoprotein 1, cardiolipin and other molecules, as well as functional assays for lupus anticoagulant. The presence of aPL can lead to endothelial dysfunction or a hypercoagulable state through prothrombotic and antifibrinolytic mechanisms.
Open in Who Shared Issue with article?
See all 47 licensed articles (51 Total)